Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 461

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial

Open access
Spyropoulos, Alex C., Goldin, Mark, Giannis, Dimitrios, Diab, Wassim, Wang, Janice, Khanijo, Sameer, Mignatti, Andrea, Gianos, Eugenia, Cohen, Marc, Sharifova, Gulru, Lund, Jeet M., Tafur, Alfonso, Lewis, Paul A., Cohoon, Kevin P., Rahman, Husneara, Sison, Cristina P., Lesser, Martin L., Ochani, Kanta, Agrawal, Nirav, Hsia, Judith, Anderson, Victoria E., Bonaca, Marc, Halperin, Jonathan L., Weitz, Jeffrey I., HEP-COVID Investigators, Ohanesian, Lori, Glater, Michelle, Ho, Christopher, Iakovou, Annamaria, Ying, Daniel, Dastagir, Manile, Convissar, Alex, Aujla, Seerat, Mathew, Elizabeth, Thiyagarajan, Vani, Lewis, Tricia, Gruberg, Luis, Maccaro, Paul, Kuziw, Dana, Pandhi, Bhumi, Surguladze, George, Eapen, Ashley M., Pantea, Alexandra, Suen, Phyllis, Flynt, John, Krzyzak, Michael, Sharma, Kamal, Steadham, Amanda, McLean, Sherry L., Herring, Karen, Maroney, Karen, Zorriasateyn, Kambiz, Vargas, Bernardo, Durante, Marisa, Bhokary, Ujala, Pierchala, Linda, Fisher, Elizabeth A., Oxenberg, Debi L., Sabados, Alison, Chaudhary, Omair A., Schultz, Shelley, Cotey, Sue, Hess, Connie, Cruse, Hope, Uy, Daniel, Sharma, Sunita, Molina, Kevin, Jagat, Daliya, Dehali, Bandyopadhyay · 2021 · JAMA Internal Medicine

Abstract

Importance: Hospitalized patients with COVID-19 are at risk for venous and arterial thromboembolism and death. Optimal thromboprophylaxis dosing in high-risk patients is unknown. Objective: To evaluate the effects of therapeutic-dose low-molecular-weight heparin (LMWH) vs institutional standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19. Design, Setting, and Participants: The HEP-COVID multicenter randomized clinical trial recruited hospitalized adult patients with COVID-19 with D-dimer levels more than 4 times the upper limit of normal or sepsis-induced coagulopathy score of 4 or greater from May 8, 2020, through May 14, 2021, at 12 academic centers in the US. Interventions: Patients were randomized to institutional standard prophylactic or intermediate-dose LMWH or unfractionated heparin vs therapeutic-dose enoxaparin, 1 mg/kg subcutaneous, twice daily if creatinine clearance was 30 mL/min/1.73 m2 or greater (0.5 mg/kg twice daily if creatinine clearance was 15-29 mL/min/1.73 m2) throughout hospitalization. Patients were stratified at the time of randomization based on intensive care unit (ICU) or non-ICU status. Main Outcomes and Measures: The primary efficacy outcome was venous thromboembolism (VTE), arterial thromboembolism (ATE), or death from any cause, and the principal safety outcome was major bleeding at 30 ± 2 days. Data were collected and adjudicated locally by blinded investigators via imaging, laboratory, and health record data. Results: Of 257 patients randomized, 253 were included in the analysis (mean [SD] age, 66.7 [14.0] years; men, 136 [53.8%]; women, 117 [46.2%]); 249 patients (98.4%) met inclusion criteria based on D-dimer elevation and 83 patients (32.8%) were stratified as ICU-level care. There were 124 patients (49%) in the standard-dose vs 129 patients (51%) in the therapeutic-dose group. The primary efficacy outcome was met in 52 of 124 patients (41.9%) (28.2% VTE, 3.2% ATE, 25.0% death) with standard-dose heparins vs 37 of 129 patients (28.7%) (11.7% VTE, 3.2% ATE, 19.4% death) with therapeutic-dose LMWH (relative risk [RR], 0.68; 95% CI, 0.49-0.96; P = .03), including a reduction in thromboembolism (29.0% vs 10.9%; RR, 0.37; 95% CI, 0.21-0.66; P < .001). The incidence of major bleeding was 1.6% with standard-dose vs 4.7% with therapeutic-dose heparins (RR, 2.88; 95% CI, 0.59-14.02; P = .17). The primary efficacy outcome was reduced in non-ICU patients (36.1% vs 16.7%; RR, 0.46; 95% CI, 0.27-0.81; P = .004) but not ICU patients (55.3% vs 51.1%; RR, 0.92; 95% CI, 0.62-1.39; P = .71). Conclusions and Relevance: In this randomized clinical trial, therapeutic-dose LMWH reduced major thromboembolism and death compared with institutional standard heparin thromboprophylaxis among inpatients with COVID-19 with very elevated D-dimer levels. The treatment effect was not seen in ICU patients. Trial Registration: ClinicalTrials.gov Identifier: NCT04401293.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamainternmed.2021.6203

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 461

Metadata

Authors
Spyropoulos, A. C., Goldin, M., Giannis, D., Diab, W., Wang, J., Khanijo, S., Mignatti, A., Gianos, E., Cohen, M., Sharifova, G., Lund, J. M., Tafur, A., Lewis, P. A., Cohoon, K. P., Rahman, H., Sison, C. P., Lesser, M. L., Ochani, K., Agrawal, N., Hsia, J., Anderson, V. E., Bonaca, M., Halperin, J. L., Weitz, J. I., HEP-COVID Investigators, Ohanesian, L., Glater, M., Ho, C., Iakovou, A., Ying, D., Dastagir, M., Convissar, A., Aujla, S., Mathew, E., Thiyagarajan, V., Lewis, T., Gruberg, L., Maccaro, P., Kuziw, D., Pandhi, B., Surguladze, G., Eapen, A. M., Pantea, A., Suen, P., Flynt, J., Krzyzak, M., Sharma, K., Steadham, A., McLean, S. L., Herring, K., Maroney, K., Zorriasateyn, K., Vargas, B., Durante, M., Bhokary, U., Pierchala, L., Fisher, E. A., Oxenberg, D. L., Sabados, A., Chaudhary, O. A., Schultz, S., Cotey, S., Hess, C., Cruse, H., Uy, D., Sharma, S., Molina, K., Jagat, D., & Dehali, B.
Venue
JAMA Internal Medicine
Published
2021-12-01
Volume
181
Issue
12
Pages
1612
ISSN
2168-6106 (ISSN-L)
OpenAlex
W3202637221
Cited by
461
References
30
FWCI
72.66
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.